Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

Summary

This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's disease.

Timeline

Start

2023-04-18

Primary completion

2025-08-22

Completion

2025-09-11

Drugs

Indications